This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fang J et al. (2002) PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 59: 889–893
De Marzo AM et al. (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155: 1985–1992
Riss J et al. (2006) Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res 66: 7216–7224
van der Cruijsen-Koeter IW et al. (2006) Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology 68: 615–620
Lu-Yao G et al. (2002) Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325: 740
Oliver SE et al. (2000) Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355: 1788–1789
Taylor ML et al. (2005) Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 37: 506–512
Fleming LE et al. (1999) Mortality in a cohort of licensed pesticide applicators in Florida. Occup Environ Med 56: 14–21
Collin SM et al. (2008) Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol 9: 445–452
Byar DP (1973) Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32: 1126–1130
Shaw GL et al. (2007) International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1,446 patients. BJU Int 99: 1056–1065
Studer UE et al. (2006) Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24: 1868–1876
Iversen P et al. (1995) Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl 172: 65–72
Bill-Axelson A et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977–1984
Coffey JC et al. (2003) Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 4: 760–768
Oliver RT (1995) Does surgery disseminate or accelerate cancer? Lancet 346: 1506–1507
Freed CR et al. (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344: 710–709
Eastham JA and Scardino PT (2000) Radical Prostatectomy for Clinical Stage T1 and T2 Prostate Cancer. In Comprehensive Textbook of Genitourinary Oncology, 166–189 (Eds Vogelzang NJ et al.) Philadelphia: Lippincott Williams & Wilkins
Munding MD et al. (2001) Pilot study of changes in stretched penile length 3 months after radical retropubic prostatectomy. Urology 58: 567–569
Donovan JL et al. (2003) Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). J Clin Epidemiol 56: 605–609
National Institute for Health and Clinical Excellence (online 30 September 2002) Improving Outcomes in Urological Cancers [http://www.nice.org.uk/ nicemedia/pdf/Urological_Manual.pdf] (accessed 3 December 2008)
Lein M et al. (2006) Complications, urinary continence, and oncologic outcome of 1,000 laparoscopic transperitoneal radical prostatectomies–experience at the Charité Hospital Berlin, Campus Mitte. Eur Urol 50: 1278–1282
National Institute for Health and Clinical Excellence (22 November 2006) Laparoscopic radical prostatectomy [http://www.nice.org.uk/guidance/IPG193] (accessed 3 December 2008)
Ficarra V et al. (2007) Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review. Eur Urol 51: 45–55
Zagars GK et al. (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22: 640–647
Burgess SV et al. (2006) Cost analysis of radical retropubic, perineal, and robotic prostatectomy. J Endourol 20: 827–830
Zietman AL et al. (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294: 1233–1239
Liauw SL et al. (2006) Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys 66: 669–673
Fletcher SG et al. (2006) Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 66: 1092–1099
D'Amico AV et al. (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821–827
Tward JD et al. (2006) Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer 107: 2392–2400
Miller DC et al. (2005) Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23: 2772–2780
Sakr WA et al. (1995) Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract 191: 838–841
Cuzick J et al. (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95: 1186–1194
Hardie C et al. (2005) Early outcomes of active surveillance for localized prostate cancer. BJU Int 95: 956–960
Da Silva CF et al. (2000) Intermittent MAB versus continuous MAB (phase III) [abstract #MP6.106]. BJU Int 86 (Suppl 3): 219–220
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Table 1
Overview of randomized trials of hormone therapy and surgery for prostate cancer (DOC 58 kb)
Supplementary Table 2
Comparison of early results of new surgical approaches to radical prostatectomy.7 (DOC 58 kb)
Supplementary Table 3
Summary of phase II trials in patients with localized prostate cancer. (DOC 58 kb)
Rights and permissions
About this article
Cite this article
Oliver, R., Neal, D. Treatment for PSA screen-detected prostate cancer: what are the options?. Nat Rev Urol 6, 132–134 (2009). https://doi.org/10.1038/ncpuro1297
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro1297